HK1012026A1 - Fusion proteins their preparaton and use - Google Patents

Fusion proteins their preparaton and use

Info

Publication number
HK1012026A1
HK1012026A1 HK98113231A HK98113231A HK1012026A1 HK 1012026 A1 HK1012026 A1 HK 1012026A1 HK 98113231 A HK98113231 A HK 98113231A HK 98113231 A HK98113231 A HK 98113231A HK 1012026 A1 HK1012026 A1 HK 1012026A1
Authority
HK
Hong Kong
Prior art keywords
fusion proteins
manner
preparaton
fusion protein
oligonucleotide
Prior art date
Application number
HK98113231A
Other languages
English (en)
Inventor
Siegfried Stengelin
Wolfgang Ulmer
Paul Habermann
Eugen Uhlmann
Brian Seed
Original Assignee
Hoechst Ag
Massachusetts Gen Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag, Massachusetts Gen Hospital filed Critical Hoechst Ag
Publication of HK1012026A1 publication Critical patent/HK1012026A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/62Insulins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62DNA sequences coding for fusion proteins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/35Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/70Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Diabetes (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HK98113231A 1989-08-29 1998-12-11 Fusion proteins their preparaton and use HK1012026A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39987489A 1989-08-29 1989-08-29
PCT/US1990/004840 WO1991003550A1 (en) 1989-08-29 1990-08-28 Fusion proteins, their preparation and use

Publications (1)

Publication Number Publication Date
HK1012026A1 true HK1012026A1 (en) 1999-07-23

Family

ID=23581315

Family Applications (1)

Application Number Title Priority Date Filing Date
HK98113231A HK1012026A1 (en) 1989-08-29 1998-12-11 Fusion proteins their preparaton and use

Country Status (20)

Country Link
EP (1) EP0489780B1 (de)
JP (1) JP3043803B2 (de)
KR (1) KR0159786B1 (de)
AT (1) ATE173018T1 (de)
AU (1) AU638277B2 (de)
CA (1) CA2065146C (de)
CY (1) CY2168B1 (de)
DE (1) DE69032743T2 (de)
DK (1) DK0489780T3 (de)
ES (1) ES2124216T3 (de)
FI (1) FI113183B (de)
GR (1) GR1005153B (de)
HK (1) HK1012026A1 (de)
HU (1) HU216069B (de)
IE (1) IE903120A1 (de)
IL (1) IL95495A (de)
NO (1) NO308667B1 (de)
PT (1) PT95111B (de)
WO (1) WO1991003550A1 (de)
ZA (1) ZA906839B (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5426036A (en) * 1987-05-05 1995-06-20 Hoechst Aktiengesellschaft Processes for the preparation of foreign proteins in streptomycetes
EP0600372B1 (de) * 1992-12-02 1997-02-05 Hoechst Aktiengesellschaft Verfahren zur Gewinnung von Proinsulin mit korrekt verbundenen Cystinbrücken
DE59409816D1 (de) * 1993-04-27 2001-09-13 Hoechst Ag Amorphe monosphärische Formen von Insulinderivaten
WO1995009914A1 (fr) * 1993-10-05 1995-04-13 Asahi Glass Company Ltd. Vecteur de multiclonage, vecteur d'expression, et production d'une proteine exogene au moyen dudit vecteur d'expression
US6001604A (en) * 1993-12-29 1999-12-14 Bio-Technology General Corp. Refolding of proinsulins without addition of reducing agents
DE4405179A1 (de) * 1994-02-18 1995-08-24 Hoechst Ag Verfahren zur Gewinnung von Insulin mit korrekt verbundenen Cystinbrücken
US5683987A (en) * 1994-07-12 1997-11-04 The Board Of Regents Of The University Of Nebraska Therapeutic oligonucleotides targeting the human MDR1 and MRP genes
DK0821006T3 (da) 1996-07-26 2004-08-16 Aventis Pharma Gmbh Insulinderivater med öget zinkbinding
DE19735711C2 (de) 1997-08-18 2001-04-26 Aventis Pharma Gmbh Verfahren zur Herstellung eines Vorläufers von Insulin oder Insulinderivaten mit korrekt verbundenen Cystinbrücken
DE19825447A1 (de) 1998-06-06 1999-12-09 Hoechst Marion Roussel De Gmbh Neue Insulinanaloga mit erhöhter Zinkbildung
DE19915938A1 (de) 1999-04-09 2000-10-19 Aventis Pharma Gmbh Herstellung von pankreatischer Procarboxypeptidase B, Isoformen und Muteinen davon und ihre Verwendung
DE19930676B4 (de) 1999-07-02 2006-01-19 Sanofi-Aventis Deutschland Gmbh Verfahren zur Stabilisierung von Insulin, Insulinderivaten und/oder deren Vorläufer in komplexen Mischungen bei deren Lagerung in wäßrigen Lösungsmitteln
US7638618B2 (en) 2001-02-20 2009-12-29 Sanofi-Aventis Deutschland Gmbh Nucleic acids encoding a hirudin and pro-insulin as superscretable peptides and for parallel improvement of the exported forms of one or more polypeptides of interest
US7202059B2 (en) 2001-02-20 2007-04-10 Sanofi-Aventis Deutschland Gmbh Fusion proteins capable of being secreted into a fermentation medium
DE10235168A1 (de) * 2002-08-01 2004-02-12 Aventis Pharma Deutschland Gmbh Verfahren zur Reinigung von Preproinsulin
US20060035316A1 (en) * 2002-11-12 2006-02-16 Sang-Yong Lee Plasmids expressing human insulin and the preparation method for human insuling thereby
DE102008003566A1 (de) 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
DE102008003568A1 (de) 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
DE102008025008A1 (de) 2008-05-24 2009-11-26 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
DE102008025007A1 (de) 2008-05-24 2009-11-26 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
KR20100111682A (ko) 2008-01-09 2010-10-15 사노피-아벤티스 도이칠란트 게엠베하 극히 지연된 시간-작용 프로필을 갖는 신규 인슐린 유도체
BRPI0907119A2 (pt) 2008-01-09 2015-07-14 Sanofi Aventis Deutschland Derivados de insulina tendo um perfil de ação de tempo extremamente retardado
KR101820024B1 (ko) 2008-10-17 2018-01-18 사노피-아벤티스 도이칠란트 게엠베하 인슐린과 glp-1 효능제의 병용물
HUE037735T2 (hu) 2009-11-13 2018-09-28 Sanofi Aventis Deutschland DesPro36exendin-4(1-39)-Lys6-NH2-t és metionint tartalmazó gyógyszerkészítmény
ES2534191T3 (es) 2009-11-13 2015-04-20 Sanofi-Aventis Deutschland Gmbh Composición farmacéutica que comprende un agonista de GLP-1, una insulina y metionina
BR112013004756B1 (pt) 2010-08-30 2020-04-28 Sanofi Aventis Deutschland uso de ave0010 para a fabricação de um medicamento para o tratamento da diabetes melito tipo 2
DK2739646T3 (en) 2011-05-10 2018-02-26 Stefan Hermann COMPREHENSIVE BUFFER SYSTEM FOR RENATURING HUMAN PROINSULIN OR PROINSULIN DERIVATIVES
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
RU2650616C2 (ru) 2011-08-29 2018-04-16 Санофи-Авентис Дойчланд Гмбх Фармацевтическая комбинация для применения при гликемическом контроле у пациентов с сахарным диабетом 2 типа
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
JP5858945B2 (ja) 2012-03-15 2016-02-10 アークレイ株式会社 酵素を用いた測定方法
JP6970615B2 (ja) 2014-12-12 2021-11-24 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング インスリングラルギン/リキシセナチド固定比処方
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第2型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第2型糖尿病病患之治療
CN113631707A (zh) * 2019-02-19 2021-11-09 普林斯顿大学理事会 折叠结构域和rna颗粒相关蛋白质结构域的光调节寡聚化和相分离的系统和方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4366246A (en) * 1977-11-08 1982-12-28 Genentech, Inc. Method for microbial polypeptide expression
US4431739A (en) * 1979-11-05 1984-02-14 Genentech, Inc. Transformant bacterial culture capable of expressing heterologous protein
US4769326A (en) * 1980-02-29 1988-09-06 The Regents Of The University Of California Expression linkers
US4652639A (en) * 1982-05-06 1987-03-24 Amgen Manufacture and expression of structural genes
EP0195680A3 (de) * 1985-03-21 1987-06-10 Immunex Corporation Proteinsynthese mit einem Identifizierungspeptid
DE3526995A1 (de) * 1985-07-27 1987-02-05 Hoechst Ag Fusionsproteine, verfahren zu ihrer herstellung und ihre verwendung

Also Published As

Publication number Publication date
DE69032743T2 (de) 1999-06-17
CA2065146C (en) 2002-07-23
NO308667B1 (no) 2000-10-09
ATE173018T1 (de) 1998-11-15
DK0489780T3 (da) 1999-07-19
HU216069B (hu) 1999-04-28
JP3043803B2 (ja) 2000-05-22
AU638277B2 (en) 1993-06-24
AU6287290A (en) 1991-04-08
NO920774D0 (no) 1992-02-27
ES2124216T3 (es) 1999-02-01
EP0489780A4 (en) 1992-08-12
FI920923A0 (fi) 1992-02-28
IL95495A (en) 1996-10-16
CA2065146A1 (en) 1991-03-01
GR1005153B (el) 2006-03-13
CY2168B1 (en) 2002-08-23
WO1991003550A1 (en) 1991-03-21
GR900100635A (el) 1991-12-30
HU9200674D0 (en) 1992-08-28
EP0489780B1 (de) 1998-11-04
JPH05501799A (ja) 1993-04-08
IE903120A1 (en) 1991-03-13
PT95111A (pt) 1991-05-22
DE69032743D1 (de) 1998-12-10
EP0489780A1 (de) 1992-06-17
PT95111B (pt) 1998-10-30
HUT60327A (en) 1992-08-28
KR0159786B1 (ko) 1998-11-16
ZA906839B (en) 1991-06-26
IL95495A0 (en) 1991-06-30
FI113183B (fi) 2004-03-15
NO920774L (no) 1992-04-28

Similar Documents

Publication Publication Date Title
HK1012026A1 (en) Fusion proteins their preparaton and use
GB2197324B (en) Process for the production of a polypeptide
ATE88501T1 (de) Rekombinante dns-expressionsvektoren.
HUT46061A (en) Dna sequences encoding hirudin-like protein and process for producing such proteins
ES8506347A1 (es) Un metodo para producir un polipeptido de tipo il-2-".
EP0431541A3 (en) Toxoplasma gondii antigen, its production and use
IL81018A (en) Fusion proteins comprising small fragments of human interleukin-2 as ballast,process for its preparation and genes,vectors and transformed host containing said fragments and used in the process
ATE419357T1 (de) Dna 19355 polypeptide, ein homolog des tumornekrosefaktors
RU93045577A (ru) Слитные полипептиды
JPS6420095A (en) Polypeptide having anti-blood coagulating action
EP0395706A4 (en) Production of gonorrheal pi proteins and vaccines
HUT40164A (en) Process for preparing signal sequency for the transformation of proteins in expression systems
DE69634757D1 (de) Vektor zur expression von n-terminal verlängerten proteinen in hefezellen
JPS6427473A (en) Human pancreas-secreting trypsin inhibitor and production thereof
IL78278A0 (en) Process for the production of polypeptides,dna sequence encoding desired polypeptide human somatomedin c polypeptide and recombinant dna molecules
JPS6474989A (en) Dna to code human lysozyme
JPS6474988A (en) Synthetic gene of cystatin c, corresponding recombinant plasmid and recombinant
IT1243286B (it) Processo per isolamento ed espressione del fattore neuronotrofico ciliare umano mediante la tecnologia del dna ricombinante.

Legal Events

Date Code Title Description
PF Patent in force
PE Patent expired

Effective date: 20100827